669 results on '"Aiba, S."'
Search Results
2. Imeglimin-mediated glycemic control in maternally inherited deafness and diabetes.
- Author
-
Ishibashi R, Hirayama K, Watanabe S, Okano K, Kuroda Y, Baba Y, Kanayama T, Ito C, Kasahara K, Aiba S, Iga R, Ohtani R, Inaba Y, Koshizaka M, Maezawa Y, and Yokote K
- Subjects
- Female, Humans, Middle Aged, Blood Glucose analysis, Glucagon, Glycemic Control, Maternal Inheritance, Hypoglycemic Agents therapeutic use, Diabetes Mellitus, Type 2, Deafness drug therapy, Deafness chemically induced, Dipeptidyl-Peptidase IV Inhibitors adverse effects, Sodium-Glucose Transporter 2 Inhibitors adverse effects
- Abstract
Mitochondrial dysfunction causes maternally inherited deafness and diabetes (MIDD). Herein, we report improved glycemic control in a 47-year-old Japanese woman with MIDD using imeglimin without major adverse effects. Biochemical tests and metabolome analysis were performed before and after imeglimin administration. Blood glucose level fluctuations were determined. Sulfonylureas, dipeptidyl peptidase-4 inhibitors (DPP4is), and sodium glucose transporter-2 inhibitors (SGLT2i) were administered to evaluate the efficacy of their combination with imeglimin. Imeglimin decreased the HbA1c and ammonia levels and increased the time-in-range, C-peptide reactivity, and glucagon level. Elevated citrulline and histamine levels were decreased by imeglimin. The hypoglycemic effect was not enhanced by imeglimin when combined with sulfonylurea or DPP4i, but the blood glucose level was improved when combined with SGLT2i. Imeglimin improved glucose concentration-dependent insulin secretion and maximized the insulin secretory capacity by improving mitochondrial function and glutamine metabolism and urea circuit abnormalities by promoting glucagon secretion. Imeglimin could improve glycemic control in MIDD., (© 2023 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
3. Successful treatment of pustulotic arthro-osteitis with amoxicillin: A case report and review of the literature.
- Author
-
Terui H, Segawa Y, Otake E, Omori R, Tsuchiyama K, Kikuchi K, Yamasaki K, Aiba S, and Asano Y
- Subjects
- Humans, Female, Amoxicillin therapeutic use, Skin pathology, Comorbidity, Osteitis diagnosis, Osteitis drug therapy, Osteitis etiology, Psoriasis pathology, Skin Diseases, Vesiculobullous complications
- Abstract
Palmoplantar pustulosis (PPP) is a chronic skin inflammatory disease characterized by sterile pustules on the palms and soles. Pustulotic arthro-osteitis (PAO) is a major comorbidity of PPP, frequently affecting the anterior chest wall. PPP and PAO are thought to be closely associated with focal infection. We report a female in her 40s who developed pustules on her palms and soles with tenderness of both sternoclavicular and left sacroiliac joints, which were not improved with non-steroidal anti-inflammatory drugs. Of note, she showed a great response to amoxicillin, resulting in the almost complete resolution of her skin lesions and arthralgia. We also reviewed previous reports to learn more about the potential therapeutic options of antibiotics for PAO., (© 2023 Japanese Dermatological Association.)
- Published
- 2023
- Full Text
- View/download PDF
4. Low proviral load in the Kumamoto strain of Japanese Brown cattle infected with the bovine leukemia virus.
- Author
-
Inenaga T, Fukuoka K, Sumida M, Aiba S, Nishikaku K, Matsuno Y, Kobayashi T, and Imakawa K
- Subjects
- Cattle, Animals, Histocompatibility Antigens Class II genetics, Proviruses genetics, Gene Frequency, Leukemia Virus, Bovine genetics, Enzootic Bovine Leukosis genetics, Cattle Diseases
- Abstract
Background: The Kumamoto strain of Japanese Brown (JBRK) cattle is a sub-breed of Wagyu and has a different genetic background than that of Japanese Black (JB) cattle. Bovine leukemia virus (BLV) is the pathogen causing enzootic bovine leukosis (EBL), the predominant type of bovine leukosis (BL). EBL is one of the most common bovine infectious diseases in dairy countries, including Japan. Some host genetic factors, including the bovine leukocyte antigen (BoLA)-DRB3 gene, have been associated with the proviral load (PVL) of BLV and/or onset of EBL. Here, we determined the number of BL cases by analyzing prefectural case records in detail. We measured the PVL of BLV-infected JBRK cattle and compared it with that obtained for other major breeds, JB and Holstein-Friesian (HF) cattle. Finally, the relationship between PVL levels and BoLA-DRB3 haplotypes was investigated in BLV-infected JBRK cattle., Results: We determined the number of BL cases recorded over the past ten years in Kumamoto Prefecture by cattle breed. A limited number of BL cases was observed in JBRK cattle. The proportion of BL cases in the JBRK was lower than that in JB and HF. The PVL was significantly lower in BLV-infected JBRK cattle than that in the JB and HF breeds. Finally, in BLV-infected JBRK cattle, the PVL was not significantly affected by BoLA-DRB3 alleles and haplotypes. BoLA-DRB3 allelic frequency did not differ between BLV-infected JBRK cattle with low PVL and high PVL., Conclusions: To our knowledge, this is the first report showing that BL occurred less in the JBRK population of Kumamoto Prefecture. After BLV-infection, the PVL was significantly lower in JBRK cattle than that in JB and HF breeds. The genetic factors implicated in maintaining a low PVL have yet to be elucidated, but the BoLA-DRB3 haplotypes are likely not involved., (© 2023. BioMed Central Ltd., part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
5. An international validation study of the interleukin-2 luciferase leukocyte toxicity test (IL-2 Luc LTT) to evaluate potential immunosuppressive chemicals and its performance after use with the interleukin-2 luciferase assay (IL-2 Luc assay).
- Author
-
Yutaka K, Rie Y, Iwaki T, Fujimura C, Ohmiya Y, Nakajima Y, Omori T, Corsini E, Inoue T, Rogen EL, Kojima H, and Aiba S
- Subjects
- Reproducibility of Results, Luciferases, Toxicity Tests methods, Interleukin-2, Immunosuppressive Agents toxicity
- Abstract
We previously reported that the IL-2 Luc LTT can detect immunosuppressive effects of drugs that are attributed to their antimitotic activity. Here, we report an official validation study of the IL-2 Luc LTT. In the Phase I study that evaluated five coded chemicals, the within-laboratory reproducibility of three independent laboratories was 100.0%. In the combined results of the Phase I and II studies that evaluated 20 coded chemicals, the between-laboratory reproducibility was 92.0%. When compared with the reference data based on the previously-reported immunotoxicological information, the predictivity of the combined Phase I and II studies was 76.0% for Lab A and 72.0% for Labs B and C. In contrast, in the study in which the lead laboratory examined 37 non-pharmaceutical chemicals, the predictivity of the IL-2 Luc LTT and the IL-2 Luc assay was 48.6% and 64.9%, respectively, whereas that of the combined assays was 74.3%. It is clear that an integrated approach combining multiple assays is necessary for the development of in vitro immunosuppression testing. These data suggest that the IL-2 Luc LTT alone is not sufficient as a component of the integrated approach, but the combination of the IL-2 Luc assay and IL-2 Luc LTT is promising., Competing Interests: Declaration of Competing Interest None., (Copyright © 2022 Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
6. Possible Efficacy of Vedolizumab, an Anti-α4β7 Integrin Antibody, in Palmoplantar Pustulosis.
- Author
-
Terui H, Moroi R, Masamune A, Aiba S, and Yamasaki K
- Abstract
Palmoplantar pustulosis (PPP) is a chronic skin inflammatory disease in which blisters and pustules repeatedly develop on palms and soles. PPP is often refractory to topical therapy, oral therapy, phototherapy, and biologics that are usually applied for PPP. We report a patient with PPP improved by vedolizumab (anti-α4β7 integrin antibody) treatment for ulcerative colitis, suggesting the possibility of a new molecular target for PPP therapy., Competing Interests: The authors have no conflicts of interest to declare., (© 2023 The Author(s). Published by S. Karger AG, Basel.)
- Published
- 2023
- Full Text
- View/download PDF
7. The Antimicrobial Peptide Cathelicidin Exerts Immunomodulatory Effects via Scavenger Receptors.
- Author
-
Amagai R, Takahashi T, Terui H, Fujimura T, Yamasaki K, Aiba S, and Asano Y
- Subjects
- Cyclooxygenase 2 genetics, Poly I-C, Humans, Cathelicidins immunology, Cathelicidins pharmacology, Receptors, Scavenger immunology, Immunomodulation genetics, Immunomodulation immunology
- Abstract
An active form of cathelicidin antimicrobial peptide, LL-37, has immunomodulatory and stimulatory effects, though the specific pathways are not clear. The purpose of this study was to identify the cellular pathways by which LL-37 amplifies the inflammation induced by damage-associated molecular patterns (DAMPs). We performed DNA microarray, reverse transcription polymerase chain reaction, immunoblotting, and proximity ligation assays using cultured keratinocytes treated with LL-37 and/or the DAMP poly(I:C), a synthetic double-stranded RNA. In contrast to the combination of LL-37 and poly(I:C), LL-37 alone induced genes related to biological metabolic processes such as VEGFA and PTGS2 (COX-2). Inhibition of FPR2, a known receptor for cathelicidin, partially suppressed the induction of VEGFA and PTGS2. Importantly, VEGFA and PTGS2 induced by LL-37 alone were diminished by the knockdown of scavenger receptors including SCARB1 (SR-B1), OLR1 (SR-E1), and AGER (SR-J1). Moreover, LL-37 alone, as well as the combination of LL-37 and poly(I:C), showed proximity to the scavenger receptors, indicating that LL-37 acts via scavenger receptors and intermediates between them and poly(I:C). These results showed that the broad function of cathelicidin is generally dependent on scavenger receptors. Therefore, inhibitors of scavenger receptors or non-functional mock cathelicidin peptides may serve as new anti-inflammatory and immunosuppressive agents.
- Published
- 2023
- Full Text
- View/download PDF
8. Cohort study of subclinical sensitization against galactose-α-1,3-galactose in Japan: Prevalence and regional variations.
- Author
-
Nakagawa Y, Chinuki Y, Ogino R, Yamasaki K, Aiba S, Ugajin T, Yokozeki H, Kitamura K, and Morita E
- Subjects
- Male, Cattle, Animals, Humans, Galactose, Prevalence, Cetuximab adverse effects, Cohort Studies, Japan epidemiology, Immunoglobulin E, Allergens, Epitopes, Tick Bites, Food Hypersensitivity epidemiology, Food Hypersensitivity diagnosis
- Abstract
Sensitization to galactose-α-1,3-galactose (α-Gal) leads to the development of α-Gal syndrome, which includes red meat allergy and cetuximab-induced anaphylaxis. Since tick bites represent the main cause of α-Gal sensitization, it was speculated that sensitization to α-Gal occurs throughout Japan. However, few cohort studies have investigated α-Gal sensitization in Japan. Therefore, we aimed to elucidate the subclinical sensitization rate to α-Gal in Japan. Sera were obtained from 300 participants without food or cetuximab allergy at Shimane University Hospital (Shimane prefecture), Tokyo Medical and Dental University Hospital (Tokyo metropolis), and Tohoku University Hospital (Miyagi prefecture). ImmunoCAP-bovine thyroglobulin (BTG), ImmunoCAP-beef, and IgE immunoblotting with cetuximab were performed to detect α-Gal-specific IgE. Clinical information was collected from participants using a questionnaire. The overall positivity rate of ImmunoCAP-BTG was 4.0% without significant inter-institute differences, whereas that for ImmunoCAP-beef was 9.7% with a significant inter-institute difference. Tokyo Medical and Dental University Hospital (19.0%) had the highest positivity rate. The positivity rate based on cetuximab IgE immunoblotting was 2.7%, without any significant inter-institute differences. The overall positivity rate for both ImmunoCAP-BTG and cetuximab immunoblotting was 2.0%, with a significant inter-institute difference; 5.0% of Shimane University Hospital was the highest. Two cases showed sensitization against the non-α-Gal epitope of cetuximab. The overall positivity rate for both ImmunoCAP-beef and cetuximab immunoblotting was 1.3%, without significant inter-institute differences. Male sex was associated with positive beef-specific IgE. The prevalence of subclinical sensitization to α-Gal is estimated at 2.0%-4.0% in Japan and may be higher in rural areas, supporting an association between tick bites and α-Gal sensitization. In contrast, the prevalence of subclinical sensitization to beef is 9.7% in Japan and is highest in Tokyo Metropolis, suggesting the presence of another IgE-binding epitope apart from α-Gal and another sensitization route in the sensitization to beef IgE., (© 2022 Japanese Dermatological Association.)
- Published
- 2022
- Full Text
- View/download PDF
9. Staphylococcus aureus skin colonization promotes SLE-like autoimmune inflammation via neutrophil activation and the IL-23/IL-17 axis.
- Author
-
Terui H, Yamasaki K, Wada-Irimada M, Onodera-Amagai M, Hatchome N, Mizuashi M, Yamashita R, Kawabe T, Ishii N, Abe T, Asano Y, and Aiba S
- Subjects
- Animals, Mice, Adaptor Proteins, Signal Transducing, Autoantibodies, Inflammation, Interleukin-23, Neutrophil Activation, Staphylococcus aureus, Lupus Erythematosus, Systemic, Staphylococcal Infections
- Abstract
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by inflammation of various organs such as skin, kidneys, bones, and brain and the presence of autoantibodies. Although the cause of SLE is not completely understood, environmental factors, genetic susceptibility, hormone factors, and environmental factors are thought to play essential roles in the pathogenesis of SLE. Among environmental factors, the microbiota are linked to the development of different autoimmune diseases. The microbiota in the nasal cavity and gut are involved in SLE development, but the influence of skin microbiota is still unclear. Here, we demonstrated that epithelial cell-specific IκBζ-deficient ( Nfkbiz
ΔK5 ) mice showed spontaneous skin inflammation with increased abundance of Staphylococcus aureus on the skin. When S. aureus was epicutaneously applied on NfkbizΔK5 mice, NfkbizΔK5 mice developed SLE-associated autoantibodies, anti-dsDNA antibodies, anti-Sm antibodies, and glomerulonephritis with IgG deposition. Epicutaneous S. aureus application significantly increased staphylococcal colonization on the skin of NfkbizΔK5 mice with reduced expression of several antimicrobial peptides in the skin. This staphylococcal skin colonization promoted caspase-mediated keratinocyte apoptosis and neutrophil activation, inducing the interleukin-23 (IL-23)/IL-17 immune response by activating dendritic cells and T cells. Furthermore, the subcutaneous administration of anti-IL-23p19 and anti-IL-17A antibodies alleviated the systemic autoimmune response. Together, these findings underscore epithelial-immune cross-talk disturbances caused by skin dysbiosis as an essential mediator inducing autoimmune diseases.- Published
- 2022
- Full Text
- View/download PDF
10. Evaluation of Anterior Coverage in Children With Developmental Dysplasia of the Hip Using Transverse Magnetic Resonance Imaging at 2 Years Is Predictive of Future Radiographic Coverage.
- Author
-
Tsukagoshi Y, Kamada H, Takeuchi R, Tomaru Y, Nakagawa S, Kimura M, Aiba S, Shimada H, Ikezawa Y, and Yamazaki M
- Subjects
- Acetabulum pathology, Child, Preschool, Hip Joint, Humans, Magnetic Resonance Imaging, Retrospective Studies, Carcinoembryonic Antigen, Developmental Dysplasia of the Hip diagnostic imaging
- Abstract
Background: Although normal anterior acetabular coverage provides stability to the hip, acetabular retroversion leads to femoroacetabular impingement related to hip osteoarthritis. Previous studies have focused on acetabular version and anteroposterior coverage in children with developmental dysplasia of the hip (DDH); however, the correlation between anteroposterior coverage and acetabular development is unclear. We measured anteroposterior acetabular coverage in DDH patients using transverse magnetic resonance imaging (MRI) and subsequent bony acetabular growth, and evaluated the correlation of those findings., Methods: We evaluated 37 DDH (dislocations) in 36 patients who underwent MRI at 2 years of age. The mean age was 2.2±0.3 years at the time of MRI (1.6±0.4 y after reduction) and 6.0±0.1 years at the time of plain radiography for the Severin classification. On MRI scans, we measured the cartilaginous center-edge angle (CCEA) and cartilaginous acetabular-head index (CAHI) in the coronal plane and the anterior and posterior cartilaginous center-edge angles (AC-CEA and PC-CEA, respectively) in the transverse plane. Severin I or II was defined as a good outcome and III or IV as a poor outcome., Results: In the evaluations conducted at 2 years of age, the mean CCEA, CAHI, AC-CEA, and PC-CEA were 14±9 degrees, 66%±10%, 39±8 degrees, and 77±7 degrees, respectively; the CEA at 6 years of age was 13±7 degrees. Twelve and 25 hips were classified in the good and poor outcome groups, respectively. Although CCEA, CAHI, and AC-CEA were significantly associated with the outcome in a single regression analysis ( P <0.05), only AC-CEA was significant in the multiple regression analysis with a stepwise selection method ( P =0.018). The cutoff AC-CEA value for a good outcome was 38 degrees (sensitivity, 67%; specificity, 68%) using a receiver operating characteristic curve., Conclusions: Among MRI findings for acetabular cartilaginous morphology, AC-CEA was strongly associated with the outcome. Anteroposterior coverage was correlated with bony acetabular growth in childhood, and anterior coverage was particularly important for subsequent acetabular growth., Level of Evidence: Level IV-case series., Competing Interests: The authors declare no conflicts of interest., (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
11. Loss of IκBζ Drives Dentin Formation via Altered H3K4me3 Status.
- Author
-
Yuan H, Suzuki S, Terui H, Hirata-Tsuchiya S, Nemoto E, Yamasaki K, Saito M, Shiba H, Aiba S, and Yamada S
- Subjects
- Animals, Cell Differentiation, Chromatin metabolism, Dental Pulp metabolism, Dentin, Secondary metabolism, Extracellular Matrix Proteins genetics, Extracellular Matrix Proteins metabolism, Lysine genetics, Lysine metabolism, Mice, Mice, Knockout, NF-kappa B metabolism, Odontoblasts metabolism, Adaptor Proteins, Signal Transducing genetics, Dentin metabolism, Histones genetics, Histones metabolism
- Abstract
Enforced enrichment of the active promoter marks trimethylation of histone H3 lysine 4 (H3K4me3) and acetylation of histone H3 lysine 27 (H3K27ac) by inhibiting histone demethylases and deacetylases is positively associated with hard tissue formation through the induction of osteo/odontogenic differentiation. However, the key endogenous epigenetic modulator of odontoblasts to regulate the expression of genes coding dentin extracellular matrix (ECM) proteins has not been identified. We focused on nuclear factor (NF)-κB inhibitor ζ (IκBζ), which was originally identified as the transcriptional regulator of NF-κB and recently regarded as the NF-κB-independent epigenetic modulator, and found that IκBζ null mice exhibit a thicker dentin width and narrower pulp chamber, with aged mice having more marked phenotypes. At 6 mo of age, dentin fluorescent labeling revealed significantly accelerated dentin synthesis in the incisors of IκBζ null mice. In the molars of IκBζ null mice, marked tertiary dentin formation adjacent to the pulp horn was observed. Mechanistically, the expression of COL1A2 and COL1A1 collagen genes increased more in the odontoblast-rich fraction of IκBζ null mice than in wild type in vivo, similar to human odontoblast-like cells transfected with small interfering RNA for IκBζ compared with cells transfected with control siRNA in vitro. Furthermore, the direct binding of IκBζ to the COL1A2 promoter suppressed COL1A2 expression and the local active chromatin status marked by H3K4me3. Based on whole-genome identification of H3K4me3 enrichment, ECM and ECM organization-related gene loci were selectively activated by the knockdown of IκBζ, which consistently resulted in the upregulation of these genes. Collectively, this study suggested that IκBζ is the key negative regulator of dentin formation in odontoblasts by inhibiting dentin ECM- and ECM organization-related gene expression through an altered local chromatin status marked by H3K4me3. Therefore, IκBζ is a potential target for epigenetically improving the clinical outcomes of dentin regeneration therapies such as pulp capping.
- Published
- 2022
- Full Text
- View/download PDF
12. Runx1 and Runx2 inhibit fibrotic conversion of cellular niches for hematopoietic stem cells.
- Author
-
Omatsu Y, Aiba S, Maeta T, Higaki K, Aoki K, Watanabe H, Kondoh G, Nishimura R, Takeda S, Chung UI, and Nagasawa T
- Subjects
- Animals, Bone Marrow metabolism, Core Binding Factor Alpha 1 Subunit genetics, Core Binding Factor Alpha 1 Subunit metabolism, Core Binding Factor Alpha 2 Subunit genetics, Core Binding Factor Alpha 2 Subunit metabolism, Fibrosis, Hematopoiesis genetics, Mice, Hematopoietic Stem Cells metabolism, Stem Cell Niche
- Abstract
In bone marrow, special microenvironments, known as niches, are essential for the maintenance of hematopoietic stem cells (HSCs). A population of mesenchymal stem cells, termed CXC chemokine ligand 12 (CXCL12)-abundant reticular (CAR) cells or leptin receptor-expressing cells are the major cellular component of HSC niches. The molecular regulation of HSC niche properties is not fully understood. The role of Runx transcription factors, Runx1 and Runx2 in HSC cellular niches remains unclear. Here we show that Runx1 is predominantly expressed in CAR cells and that mice lacking both Runx1 and Runx2 in CAR cells display an increase in fibrosis and bone formation with markedly reduced hematopoietic stem and progenitor cells in bone marrow. In vitro, Runx1 is induced by the transcription factor Foxc1 and decreases fibrotic gene expression in CAR cells. Thus, HSC cellular niches require Runx1 or Runx2 to prevent their fibrotic conversion and maintain HSCs and hematopoiesis in adults., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
13. Characterization of rosacea patients in Tohoku area of Japan: Retrospective study of 340 rosacea cases.
- Author
-
Wada-Irimada M, Yamamoto H, Terui H, Omori-Shimada R, Yamazaki E, Kikuchi K, Aiba S, and Yamasaki K
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Erythema, Female, Humans, Immunoglobulin E, Japan epidemiology, Male, Middle Aged, Retrospective Studies, Young Adult, Rosacea diagnosis, Rosacea epidemiology, Rosacea therapy
- Abstract
Rosacea is a chronic inflammatory skin disease with facial redness and acne-like papules and pustules. The characteristics and background of rosacea patients in Japan have not been well documented. In this study, we retrospectively collected the medical information of rosacea patients, and investigated the background, complications, exacerbating factors, and status of allergy. Between January 2010 and December 2020, 431 cases were diagnosed as rosacea or rosacea-like dermatitis. We selected 340 patients, in which we could confirm telangiectasia on facial skin. Females and males numbered 266 and 74, respectively. The average age of the first visit was 51.5 years, and the youngest and oldest were 11 and 88 years old. Among 340 cases, 323 had erythematotelangiectatic rosacea, 97 papulopustular rosacea, 20 phymatous rosacea presenting as rhinophyma, and four had symptoms of ocular rosacea. The most common complication was hay fever (93 individuals, 27.4%), and 66 (19.4%) had a medical history of contact dermatitis. Temperature differences (141 individuals, 41.5%) were the most common exacerbating factor followed by sunlight exposure (60 individuals, 17.6%). Seventy-eight individuals received allergen-specific immunoglobulin (Ig)E tests, and IgE for cedar was the most frequently observed (46 individuals, 59.0%). High frequencies of IgE for Dermatophagoides pteronyssinus or D. farinae (33 individuals, 42.3%) and house dust I (31 individuals, 39.7%) suggested that environmental conditions at home would affect rosacea symptoms. Since the facial skin is exposed to environmental stimuli every moment, this retrospective observation suggested the importance of the daily lifestyle guidance as well as medical treatments., (© 2022 Japanese Dermatological Association.)
- Published
- 2022
- Full Text
- View/download PDF
14. Functional Analysis of the Transcriptional Regulator IκB-ζ in Intestinal Homeostasis.
- Author
-
Sasaki T, Nagashima H, Okuma A, Yamauchi T, Yamasaki K, Aiba S, So T, Ishii N, Owada Y, MaruYama T, and Kobayashi S
- Subjects
- Animals, Dextran Sulfate toxicity, Homeostasis, Humans, Interferon-gamma, Intestinal Mucosa metabolism, Mice, Mice, Inbred C57BL, Signal Transduction, Colitis metabolism
- Abstract
Background: The Toll-like receptor signaling pathway contributes to the regulation of intestinal homeostasis through interactions with commensal bacteria. Although the transcriptional regulator IκB-ζ can be induced by Toll-like receptor signaling, its role in intestinal homeostasis is still unclear., Aims: To investigate the role of IκB-ζ in gut homeostasis., Methods: DSS-administration induced colitis in control and IκB-ζ-deficient mice. The level of immunoglobulins in feces was detected by ELISA. The immunological population in lamina propria (LP) was analyzed by FACS., Results: IκB-ζ-deficient mice showed severe inflammatory diseases with DSS administration in the gut. The level of IgM in the feces after DSS administration was less in IκB-ζ-deficient mice compared to control mice. Upon administration of DSS, IκB-ζ-deficient mice showed exaggerated intestinal inflammation (more IFN-g-producing CD4
+ T cells in LP), and antibiotic treatment canceled this inflammatory phenotype., Conclusion: IκB-ζ plays a crucial role in maintaining homeostasis in the gut., (© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)- Published
- 2022
- Full Text
- View/download PDF
15. Nodal anaplastic large cell lymphoma with lymphomatoid papulosis following treatment of initially presumed atopic dermatitis with dupilumab: A case report.
- Author
-
Amagai M, Ozawa M, Amagai R, Ohuchi K, Muto Y, Kambayashi Y, Aiba S, and Fujimura T
- Subjects
- Antibodies, Monoclonal, Humanized adverse effects, Humans, Dermatitis, Atopic, Lymphoma, Large-Cell, Anaplastic diagnosis, Lymphoma, Large-Cell, Anaplastic drug therapy, Lymphoma, Large-Cell, Anaplastic pathology, Lymphomatoid Papulosis diagnosis, Lymphomatoid Papulosis drug therapy, Lymphomatoid Papulosis pathology, Skin Neoplasms diagnosis, Skin Neoplasms drug therapy, Skin Neoplasms pathology
- Published
- 2022
- Full Text
- View/download PDF
16. A retrospective study evaluating the outcomes of high-dose methylprednisolone pulse therapy for 483 patients with moderate-to-severe alopecia areata.
- Author
-
Wada-Irimada M, Mizuashi M, Takahashi T, Tojo G, Onami K, Shido K, Otake E, Yusa S, Tanita K, Yamazaki E, Aiba S, and Yamasaki K
- Subjects
- Humans, Methylprednisolone, Pulse Therapy, Drug, Retrospective Studies, Treatment Outcome, Alopecia Areata chemically induced, Alopecia Areata drug therapy
- Published
- 2021
- Full Text
- View/download PDF
17. Ehlers-Danlos syndrome type IV with a novel COL3A1 exon 14 skipping variation confirmed by Tohoku Medical Megabank Organization genomic database.
- Author
-
Shido K, Kojima K, Yoshida-Akai S, Kikuchi K, Hatamochi A, Aiba S, and Yamasaki K
- Subjects
- Cohort Studies, Collagen, Collagen Type III genetics, Exons, Female, Genomics, Humans, Mutation, Ehlers-Danlos Syndrome diagnosis, Ehlers-Danlos Syndrome genetics
- Abstract
A novel COL3A1 variant was identified in a Japanese case of Ehlers-Danlos syndrome type IV (EDS-IV) with a characteristic "Madonna" face, fragile uterus, and easy bruising in addition to a history of cavernous sinus fistula. We confirmed variable diameters of collagen fibrils in the dermis and decrease in type 3 collagen production from cultured fibroblasts. Genomic DNA sequencing of the COL3A1 region and COL3A1 cDNA sequence expressing in cultured fibroblasts identified that a nucleotide variation at c.951+2T>G on intron 14 leads to skipping of exon 14 in COL3A1 cDNA. The novel variation in the splice site of COL3A1 region g.IVS14+2T>G was not listed in the EDS-IV pathogenic genetic databases including Human Gene Mutation Database, ClinVar, and Leiden Open Variation Database. Using the whole genome sequence database of 8380 Japanese individuals reported by the Tohoku Medical Megabank Organization (ToMMo) cohort study, we also confirmed that COL3A1 g.IVS14+2T>G was not a common single nucleotide variation in the Japanese population, although 13 EDS-related COL3A1 variants were identified in the ToMMo database of 8380 Japanese individuals. These results demonstrated that our case of EDS-IV was a result of the novel variation of COL3A1 g.IVS14+2T>G. These statistical genetics approaches with the combination of the ToMMo database of 8380 Japanese individuals and pathogenic genetic databases are a useful method to confirm the uniqueness of novel variation in Japanese., (© 2021 Japanese Dermatological Association.)
- Published
- 2021
- Full Text
- View/download PDF
18. Body mass index, HbA1c and serum C-reactive protein are predictors of secondary failure in infliximab continuance for Japanese psoriasis patients: A hospital-based retrospective case-control study.
- Author
-
Terui H, Asano M, Shimada-Omori R, Tsuchiyama K, Takahashi T, Nasu-Tamabuchi M, Hagiwara-Takita A, Kusakari Y, Ohtani T, Aiba S, and Yamasaki K
- Subjects
- Body Mass Index, Case-Control Studies, Glycated Hemoglobin, Hospitals, Humans, Infliximab therapeutic use, Japan, Retrospective Studies, Treatment Outcome, C-Reactive Protein, Psoriasis drug therapy
- Abstract
Biologics has had a great impact on psoriasis treatment as well as the life of psoriasis patients. Infliximab (IFX), one of the biologics targeting tumor necrosis factor (TNF), is the first of the biologics introduced to Japanese psoriasis patients. Many patients had benefits of IFX from initial applications and sustained remission of skin lesions and arthritis. Some, however, fall into so-called secondary failure, in which patients become less responsive to IFX when the treatment is repeated. The mechanism of secondary failure and the background of patients with secondary failure have not been completely elucidated. To address this issue, we retrospectively evaluated psoriasis patients treated with IFX in our department. In this retrospective, single-center, case-control study based on the clinical record, a total of 34 patients were enrolled. We excluded 7 patients who discontinued IFX because of adverse events of IFX. We divided other 27 patients into two groups; 16 patients who kept using IFX (Continuance group); and 11 patients who switched to other treatments (Discontinuance group). Among various clinical features, body mass index (BMI), HbA1c, and serum CRP level were significantly higher in the Discontinuance group than the Continuance group. The results indicated that these three clinical features of BMI, HbA1c and serum CRP level before treatment are the predictors of successful IFX treatment and suggest that improvement of metabolic conditions contributes to avoiding secondary failure and discontinuance of IFX., (© 2021 Japanese Dermatological Association.)
- Published
- 2021
- Full Text
- View/download PDF
19. GWAS Identified IL4R and the Major Histocompatibility Complex Region as the Associated Loci of Total Serum IgE Levels in 9,260 Japanese Individuals.
- Author
-
Shido K, Kojima K, Shirota M, Yamasaki K, Motoike IN, Hozawa A, Ogishima S, Minegishi N, Tanno K, Katsuoka F, Tamiya G, Aiba S, Yamamoto M, and Kinoshita K
- Subjects
- Genotype, Haplotypes, Humans, Polymorphism, Single Nucleotide, Genetic Loci, Genome-Wide Association Study, Hypersensitivity genetics, Immunoglobulin E blood, Interleukin-4 Receptor alpha Subunit genetics, Major Histocompatibility Complex
- Published
- 2021
- Full Text
- View/download PDF
20. Biologics modulate antinuclear antibodies, immunoglobulin E, and eosinophil counts in psoriasis patients.
- Author
-
Sugiura R, Terui H, Shimada-Omori R, Yamazaki E, Tsuchiyama K, Takahashi T, Aiba S, and Yamasaki K
- Subjects
- Antibodies, Antinuclear, Eosinophils, Humans, Immunoglobulin E, Retrospective Studies, Biological Products therapeutic use, Psoriasis drug therapy
- Abstract
Psoriasis is a chronic disease centered on tumor necrosis factor (TNF), interleukin (IL)-23, and IL-17 axis. While psoriasis patients benefit from biologics targeting TNF, IL-17s, and IL-23 nowadays, suppression of these molecules could modulate the balances of immune systems. However, the incidence of autoimmune disease and T-helper 2 reaction during biologic treatments for psoriasis patients is not well documented. We retrospectively examined antinuclear antibody (ANA), eosinophil counts, and immunoglobulin E (IgE) levels for psoriasis patients who underwent biologic treatments in our dermatology clinic from June 10, 2010 to January 29, 2020. A cumulative total of 199 biologic treatments were performed for a total of 128 psoriasis patients. Compared to the non-biologic group of 109 psoriasis patients who received non-biologic treatment, patients treated with infliximab showed more incidents of high ANA (14%, p = 0.039) and high eosinophils (14%, p = 0.021). The use of brodalumab increased incidents of high eosinophils (21%, p = 0.005) but did not affect increase in ANA and IgE. The increase in high IgE level was observed significantly more during the use of risankizumab (15%, p = 0.011). Methotrexate was the most frequently used concomitant systemic treatment, but methotrexate did not affect ANA, eosinophil counts, and IgE levels. Since the biologics for psoriasis treatment modulate the balance of T-helper cells, careful observation is required to detect unexpected changes of systemic immune conditions under biologic treatments., (© 2021 Japanese Dermatological Association.)
- Published
- 2021
- Full Text
- View/download PDF
21. Neutrophil Extracellular Traps as a Possible Pathomechanism of Generalized Acquired Cutis Laxa Associated with IgA-lamda Monoclonal Gammopathy of Undetermined Significance.
- Author
-
Terui H, Yamasaki K, Tamabuchi E, Tsuchiyama K, and Aiba S
- Subjects
- Humans, Immunoglobulin A, Cutis Laxa diagnosis, Extracellular Traps, Monoclonal Gammopathy of Undetermined Significance, Paraproteinemias diagnosis
- Published
- 2021
- Full Text
- View/download PDF
22. 2020 guidelines for the diagnosis and treatment of cutaneous pruritus.
- Author
-
Satoh T, Yokozeki H, Murota H, Tokura Y, Kabashima K, Takamori K, Shiohara T, Morita E, Aiba S, Aoyama Y, Hashimoto T, and Katayama I
- Subjects
- Aged, Histamine Antagonists therapeutic use, Humans, Psychophysiologic Disorders, Pruritus diagnosis, Pruritus drug therapy, Skin Diseases
- Abstract
The mechanisms underlying itch are not fully understood. Physicians usually encounter difficulty controlling itch in generalized pruritus. Since only a small percentage of patients with generalized pruritus respond to antihistamines (H
1 receptor antagonists), a variety of itch mediators and mechanisms other than histaminergic signals are considered to be involved in itch for these non-responsive patients. In 2012, we created guidelines for generalized pruritus. Those guidelines have been updated and revised to make some of the definitions, diagnostic terms, and classifications more applicable to daily clinical practice. Cutaneous pruritus as designated in these guidelines is a disease characterized by itch without an observable rash. Generalized pruritus (without skin inflammation) is defined as the presence of itch over a wide area, and not localized to a specific part of the body. This entity includes idiopathic pruritus, pruritus in the elderly, symptomatic pruritus, pregnancy-associated pruritus, drug-induced pruritus, and psychogenic pruritus. Localized pruritus (without skin inflammation) represents fixed itch localized to a specific part of the body, and includes anogenital pruritus, scalp pruritus, notalgia paresthetica, and brachioradial pruritus. These guidelines outline the current concepts and specify the diagnostic methods/treatments for cutaneous pruritus., (© 2021 Japanese Dermatological Association.)- Published
- 2021
- Full Text
- View/download PDF
23. 2020 guidelines for the diagnosis and treatment of prurigo.
- Author
-
Satoh T, Yokozeki H, Murota H, Tokura Y, Kabashima K, Takamori K, Shiohara T, Morita E, Aiba S, Aoyama Y, Hashimoto T, and Katayama I
- Subjects
- Administration, Topical, Chronic Disease, Humans, Pruritus, Skin, Prurigo drug therapy, Prurigo therapy
- Abstract
Prurigo is a treatment-resistant skin disease characterized by multiple isolated papules/nodules that cause severe itch. Prurigo papules/nodules occur either as primary lesions or as secondary lesions due to persistent scratching. The fundamental concepts and classifications of prurigo have not been sufficiently established, and considerable confusion remains regarding this topic. Clinical guidelines for chronic prurigo in Japan were published in 2012 in an attempt to reduce confusion regarding the concepts of prurigo and to standardize laboratory tests and treatments. However, the diagnostic terms for prurigo and associated concepts have changed over time, and new forms of treatment are under development. We have, thus, updated and revised the guidelines to classify prurigo based on clinical forms and causes, and disease name classifications based on the clinical form have been further simplified, such as prurigo nodularis, prurigo chronica multiformis, and prurigo (not otherwise specified). Expressions for acute, subacute, and chronic forms are not used. These guidelines outline the current concepts and specify treatments for prurigo., (© 2021 Japanese Dermatological Association.)
- Published
- 2021
- Full Text
- View/download PDF
24. Pediatric psoriasis induced by HLA-B46-Cw1 haplotype: A retrospective study of psoriasis onset after hematopoietic stem cell transplantation.
- Author
-
Terui H, Yamasaki K, Hagiwara-Takita A, Shimada-Omori R, Tsuchiyama K, Saito-Nanjo Y, Rikiishi T, Sasahara Y, and Aiba S
- Subjects
- Adolescent, Adult, Child, Child, Preschool, Genome-Wide Association Study, HLA-B Antigens, HLA-C Antigens, Haplotypes, Humans, Infant, Infant, Newborn, Retrospective Studies, Young Adult, Hematopoietic Stem Cell Transplantation adverse effects, Pediatrics, Psoriasis etiology, Psoriasis genetics
- Abstract
Genome-wide association studies have identified more than 60 susceptibility loci for psoriasis, highlighting the role of genetics in psoriasis development. Although the HLA region is suggested as the most prominent susceptibility locus, the role of the HLA haplotype in the development of psoriasis is unclear. The aim of this study is to investigate how HLA haplotype changes affect the onset of psoriasis and which HLA haplotypes are associated with the development of psoriasis. A longitudinal, retrospective case series study of children was conducted at Tohoku University Hospital in Japan, between November 1981 and October 2020. We evaluated a total of 378 pediatric patients who underwent hematopoietic stem cell transplantation in the Department of Pediatrics. The background of these patients and their HLA haplotypes before and after transplantation was assessed. Among the 378 cases, aged 0-22 years old (median age 6) identified, 117 cases received autologous transplantation, 260 cases received allogeneic transplantation, and one case received syngeneic transplantation. Only two cases developed de novo psoriasis, and these cases had acquired HLA-B46-Cw1 after allogeneic transplantation. Others who had HLA-B46-Cw1 before and after allogeneic transplantation did not develop psoriasis. Our findings suggest that the HLA-B46 and HLA-Cw1 combination contributes to the development of psoriasis in this Asian population., (© 2021 Japanese Dermatological Association.)
- Published
- 2021
- Full Text
- View/download PDF
25. Successful treatment of BRAF/MEK inhibitor-resistant advanced cutaneous melanoma with nivolumab plus ipilimumab combination therapy followed by intensity-modulated radiotherapy.
- Author
-
Okuma T, Furudate S, Kambayashi Y, Hashimoto A, Aiba S, and Fujimura T
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, CD8-Positive T-Lymphocytes, Humans, Ipilimumab therapeutic use, Mitogen-Activated Protein Kinase Kinases, Nivolumab therapeutic use, Proto-Oncogene Proteins B-raf genetics, Tumor Microenvironment, Melanoma drug therapy, Melanoma genetics, Radiotherapy, Intensity-Modulated, Skin Neoplasms drug therapy
- Abstract
BRAF kinase inhibitors in combination with MEK kinase inhibitors are among the most promising chemotherapeutic regimens for the treatment of advanced BRAF-mutant melanoma. Although the NCCN guideline for cutaneous melanoma recommended BRAF/MEK inhibitors as first-line therapies for unresectable BRAF-mutated melanoma, resistance to these drugs should be taken into account in real-world practice. Therefore, development of a protocol for BRAF/MEK inhibitor-resistant advanced melanoma is needed. In this report, a case of BRAF/MEK inhibitor-resistant advanced cutaneous melanoma that was successfully treated with nivolumab plus ipilimumab combination therapy followed by intensity-modulated radiotherapy (IMRT) is reported. In the present case, not only the locally irradiated lesion, but remote metastases including inguinal lymph nodes decreased after ipilimumab plus nivolumab followed by IMRT treatment leading to complete remission, suggesting that IMRT triggered an abscopal response. Moreover, immunohistochemical analysis showed increased CD3
+ , CD4+ , and CD8+ T cells after radio-immunotherapy (RIT). This case suggests that RIT might break the tolerance in the tumor microenvironment and induce a systemic anti-melanoma immune response., (© 2021 Japanese Dermatological Association.)- Published
- 2021
- Full Text
- View/download PDF
26. Optimization of the IL-2 Luc assay for immunosuppressive drugs: a novel in vitro immunotoxicity test with high sensitivity and predictivity.
- Author
-
Kimura Y, Terui H, Fujimura C, Amagai R, Takahashi T, and Aiba S
- Subjects
- Cell Line, Humans, Mitosis drug effects, Predictive Value of Tests, Promoter Regions, Genetic, Sensitivity and Specificity, Toxicity Tests methods, Antineoplastic Agents toxicity, Immunosuppressive Agents toxicity, Interleukin-2 genetics, Luciferases genetics
- Abstract
We have reported that the IL-2 Luc assay can detect the effects of chemicals on IL-2 promoter activity by using a dual reporter cell line, 2H4 cells that measure IL-2 promoter-driven luciferase activity (IL2LA) and GAPDH promoter-driven luciferase activity (GAPLA). Since the IL-2 Luc assay cannot detect immunosuppressive drugs that are antimitotic towards rapidly proliferating cells, we attempted to establish a new assay to detect these chemicals by taking advantage of the dual reporter cell properties of 2H4 cells. We first determined the optimal incubation time with drugs and the seeding cell density, and confirmed that the change in GAPLA and IL2LA levels reflects the change in cell count and IL-2 production of 2H4 cells after drug treatment. We designed the IL-2 luciferase lymphotoxicity test (IL-2 Luc LTT) to detect the antimitotic effects of chemicals by modifying the protocol and criteria of the IL-2 Luc assay. To determine the performance of the IL-2 Luc LTT and that of the combination of the IL-2 Luc LTT and the IL-2 Luc assay, we examined 46 drugs: 19 immunosuppressive drugs with different mechanisms of action, 12 anti-cancer drugs, and 15 non-immunosuppressive drugs. The performances of the IL-2 Luc LTT, the IL-2 Luc assay and their combination were 43.3%, 61.3%, and 93.3%, respectively, for sensitivity, 84.6%, 53.3%, and 50.0%, respectively, for specificity, and 55.8%, 58.7%, and 79.5%, respectively, for accuracy. These results demonstrated that the combination of these two assays is promising for the detection of immunosuppressive drugs with different mechanisms of action., (© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2021
- Full Text
- View/download PDF
27. [A Case of Upper Urinary Tract Stone in an Infant].
- Author
-
Takemoto J, Chiba D, Otake K, Konno M, Katsumata Y, Hoshi S, Watanabe S, Aiba S, and Numahata K
- Subjects
- Female, Humans, Infant, Pregnancy, Hydronephrosis diagnostic imaging, Urinary Calculi diagnostic imaging
- Abstract
A 238-day-old female infant (122 days of age corrected for prematurity, weight 4,847 g) presented with macrohematuria. She was born at 23 weeks and3 days of pregnancy. Her birth weight was 492 g. Ultrasound revealeda 3×2 mm left ureteral stone and left hydronephrosis of grade I-II in the Society of Fetal Urology (SFU) Classification. She suffered from frequent vomiting and weight loss, and was treated with analgesics and rehydration. Eventually, left hydronephrosis was relieved, and she passed the stone at 271 days of age. The stone was 4×3×2 mm in size, and consisted of 98% calcium oxalate and2% calcium phosphate. No recurrent stone has been found during follow-up.
- Published
- 2021
- Full Text
- View/download PDF
28. Chronological changes of skin eruptions toward cold abscess formation in hyper-immunoglobulin E syndrome.
- Author
-
Fukui R, Hidaka T, Terui H, Rikiishi T, Sasahara Y, Kagimoto Y, Kusakari Y, Yamasaki K, and Aiba S
- Subjects
- Abscess diagnosis, Abscess etiology, Humans, Immunoglobulin E, STAT3 Transcription Factor, Exanthema, Job Syndrome complications, Job Syndrome diagnosis, Job Syndrome genetics
- Published
- 2021
- Full Text
- View/download PDF
29. Efficacy and safety of topical benzoyl peroxide for prolonged acneiform eruptions induced by cetuximab and panitumumab: A multicenter, phase II trial.
- Author
-
Tsutsui K, Kikuchi K, Nozawa K, Takashima A, Tsuchiyama K, Namikawa K, Aiba S, and Yamazaki N
- Subjects
- Benzoyl Peroxide therapeutic use, Cetuximab therapeutic use, Humans, Panitumumab, Quality of Life, Acneiform Eruptions drug therapy, Antineoplastic Agents therapeutic use
- Abstract
The most common adverse event of epidermal growth factor receptor inhibitors, used to treat colorectal, non-small cell lung, and head and neck cancers, is acneiform eruption, with a profound effect on treatment continuation. Prolonged acneiform eruptions treated with topical corticosteroids, a standard management, may be associated with secondary bacterial infections, thus there is a need for new treatments. We conducted a multicenter, phase II trial to evaluate the efficacy and safety of topical benzoyl peroxide for epidermal growth factor receptor inhibitor-induced prolonged acneiform eruptions. Patients with colorectal, non-small lung cell, and head and neck cancers who received epidermal growth factor receptor inhibitors for >10 weeks and had persistent acneiform eruptions were eligible. Topical benzoyl peroxide was applied to the affected area of the face once daily for 8 weeks; a clinical evaluation was performed every 2 weeks. The primary endpoint was a change in acneiform eruption severity evaluated between disease onset and end of the treatment period. The quality of life of patients was assessed using the Dermatology Life Quality Index. Of the 14 enrolled patients, 11 completed the trial. The protocol-specified grade of acneiform eruptions from baseline to week 8 improved from 2.0 to 1.0 (P < 0.01). The dermatology life quality index score from baseline to week 8 improved from 3.0 to 1.0 point (P < 0.01). No patient experienced severe adverse events. Overall, topical benzoyl peroxide may be effective for treating and managing prolonged acneiform eruptions induced by epidermal growth factor receptor inhibitors., (© 2021 Japanese Dermatological Association.)
- Published
- 2021
- Full Text
- View/download PDF
30. Phosphor-signal transducers and activator of transcription 1 signaling in mucosal lichen planus developing from metastatic bladder cancer treated with pembrolizumab.
- Author
-
Tamabuchi E, Fujimura T, Lyu C, and Aiba S
- Subjects
- Antibodies, Monoclonal, Humanized, Humans, Transducers, Lichen Planus chemically induced, Lichen Planus drug therapy, Urinary Bladder Neoplasms drug therapy
- Published
- 2021
- Full Text
- View/download PDF
31. Efficacy and safety of i.v. methylprednisolone pulse therapy for vitiligo: A retrospective study of 58 therapy experiences for 33 vitiligo patients.
- Author
-
Wada-Irimada M, Tsuchiyama K, Sasaki R, Hatchome N, Watabe A, Kimura Y, Yamasaki K, and Aiba S
- Subjects
- Aged, Child, Female, Glucocorticoids therapeutic use, Humans, Male, Methylprednisolone therapeutic use, Pulse Therapy, Drug, Retrospective Studies, Treatment Outcome, Vitiligo drug therapy
- Abstract
Systemic corticosteroid is indicated for vitiligo, especially for generalized and progressive vitiligo. However, no consensus exists yet for the dosages and modalities of systemic corticosteroid treatments for vitiligo. The purpose of this study is to validate the efficacy and safety of i.v. methylprednisolone pulse therapy (IVMP) for patients with progressive generalized vitiligo. We retrospectively reviewed the medical records of vitiligo patients treated in our institute for 10 years between January 2010 and December 2019. Among 525 vitiligo patients treated in 10 years, 33 vitiligo patients (aged, 8-78 years; 18 female and 15 males) received IVMP, a single course of daily 500 mg methylprednisolone application (8 mg/kg/day for children) for 3 consecutive days. We observed that 14 of 25 (56%) achieved stable condition without lesion progression, and 12 of 19 (63%) had more than 25% repigmentation at 6 months after IVMP. A group of Vitiligo Area Scoring Index over 10 included more patients with Vitiligo Disease Activity Score of +3 and +4 disease progression at 6 months after the IVMP. We did not observe any severe adverse events relating to the IVMP procedures. In conclusion, IVMP is a safe and effective treatment for progressive generalized vitiligo., (© 2021 Japanese Dermatological Association.)
- Published
- 2021
- Full Text
- View/download PDF
32. Improvement of diagnostic markers for resistance to Globodera pallida and application for selection of resistant germplasms in potato breeding.
- Author
-
Asano K, Shimosaka E, Yamashita Y, Narabu T, Aiba S, Sakata I, Akai K, Okamoto S, and Tamiya S
- Abstract
Occurrence of pale potato cyst nematode, Globodera pallida (Stone) Behrens, was first recorded in Japan in 2015. Among several control measures, cultivation of resistant potato ( Solanum tuberosum L.) varieties is the most effective in cost and environmental impact. As no G. pallida -resistant varieties have yet been developed in Japan, great emphasis is being placed on screening of germplasm possessing the resistance and development of the resistant varieties. In this study, we first improved previously reported DNA markers linked to the G. pallida resistance loci ( GpaIV
s adg and Gpa5 ) and then used these to screen more than 1,000 germplasms to select several candidate germplasms with resistance. We performed inoculation testing on the selected candidates and identified several resistant germplasms to the Japanese G. pallida population. Furthermore, we developed a simultaneous detection method combining three DNA markers linked to G. pallida and Globodera rostochiensis (Wollenweber) Behrens resistance loci. We validated the ability of C237-I marker to select resistant allele of GpaIVs adg and predict the presence of resistance in a Japanese breeding population. Resistant germplasms identified in this study could potentially be used to develop G. pallida -resistant varieties. The marker evaluation methods developed in this study will contribute to the efficient development of resistant varieties., (Copyright © 2021 by JAPANESE SOCIETY OF BREEDING.)- Published
- 2021
- Full Text
- View/download PDF
33. Non-immunoglobulin G4-related multifocal fibrosclerosis presenting generalized morphea-like skin lesions.
- Author
-
Chiba T, Mizuashi M, Tamabuchi E, Kanbayashi Y, Shirota Y, Fujii H, Yamasaki K, and Aiba S
- Subjects
- Humans, Retroperitoneal Fibrosis congenital, Scleroderma, Localized complications, Scleroderma, Localized diagnosis, Scleroderma, Systemic, Skin Diseases
- Published
- 2021
- Full Text
- View/download PDF
34. RB1 gene mutations are a distinct predictive factor in Merkel cell carcinoma.
- Author
-
Muto Y, Ryo E, Namikawa K, Takahashi A, Ogata D, Fujimura T, Yatabe Y, Aiba S, Yamazaki N, and Mori T
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma, Neuroendocrine genetics, Carcinoma, Neuroendocrine pathology, Female, High-Throughput Nucleotide Sequencing, Humans, Immunochemistry, Male, Middle Aged, Mutation, Neoplasm Metastasis pathology, Neoplasm Recurrence, Local pathology, Carcinoma, Merkel Cell genetics, Carcinoma, Merkel Cell pathology, Prognosis, Retinoblastoma Binding Proteins analysis, Retinoblastoma Binding Proteins genetics, Ubiquitin-Protein Ligases analysis, Ubiquitin-Protein Ligases genetics
- Abstract
Merkel cell carcinoma (MCC) is a rare cutaneous neuroendocrine carcinoma that tends to show local recurrence and metastasis. Typically, MCC is polyomavirus (MCPyV)-associated and cytokeratin 20 (CK20) positive. However, little is known about this tumor and its origins. Here, we aimed to determine the developmental origins of MCC and to identify prognostic clinicopathologic factors. Initial examinations revealed that CK20 and MCPyV expression (CK20+, MCPyV+ (60%); CK20+, MCPyV- (10%); CK20-, and MCPyV- (30%)) did not affect overall survival. With RB1 gene sequencing of FFPE specimens, which covered an entire exon, all RB1 mutation-positive cases showed positive regional lymph node and/or distant metastases (8/8 cases, 100%), whereas the frequency of the metastasis was statistically significantly lower in RB1 mutation-negative cases, (10/16 cases, 62%, P = 0.033). The results were also confirmed with immunohistochemistry, and either RB1 alterations, entire exon sequencing, or immunohistochemistry was associated with the metastasis (P = 0.007). RB1 alterations may be used to access the aggressive clinical course of MCC., (© 2021 Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
35. The IL-1 promoter-driven luciferase reporter cell line THP-G1b can efficiently predict skin-sensitising chemicals.
- Author
-
Terui H, Kimura Y, Fujimura C, and Aiba S
- Subjects
- Allergens, Animal Testing Alternatives, Animals, Cell Line, Dendritic Cells, Dermatitis, Allergic Contact diagnosis, Haptens, Humans, In Vitro Techniques, Interleukin-8, Mice, Monocytes, Promoter Regions, Genetic, Skin, Skin Tests, THP-1 Cells, Interleukin-1alpha metabolism, Luciferases metabolism
- Abstract
IL-1 functions as an essential pro-inflammatory mediator for the sensitisation of allergic contact dermatitis (ACD). However, studies conducted to date have typically used a limited number of haptens and examined their effects only on murine ACD or murine dendritic cells (DCs). It therefore remains unclear whether IL-1α and/or IL-1β is produced in ACD induced by haptens other than those commonly used in mouse ACD models, and whether they are essential for sensitisation leading to ACD in humans. In addition, it is unclear whether human DCs also produce IL-1α or IL-1β after stimulation by haptens in general. Here, we first demonstrated that 10 haptens (3 extreme, 1 strong, 3 moderate and 3 weak) increased both IL-1α mRNA and IL-1β mRNA expression by the human monocyte cell line THP-1, a commonly used surrogate of DCs in in vitro skin sensitisation tests. Next, we constructed an in vitro skin sensitisation test using a stable IL-1β reporter cell line, THP-G1b, and evaluated whether 88 haptens and 34 non-haptens increase IL-1β reporter activity. We found that 94% of 77 haptens evaluated after considering their applicability domain and solubility in the chosen media stimulated reporter activity. These studies demonstrated that most haptens, irrespective of their potency, increased IL-1β mRNA expression by THP-1 cells, confirming that human DCs also produce IL-1β after stimulation by most haptens. The luciferase assay using THP-G1b cells is thus another skin sensitisation test based on the adverse outcome pathway with reasonable performance.
- Published
- 2021
- Full Text
- View/download PDF
36. Possible roles of CXCL13/CXCR5 axis in the development of bullous pemphigoid.
- Author
-
Ohuchi K, Fujimura T, Lyu C, Amagai R, Muto Y, and Aiba S
- Subjects
- Antibodies, Autoantigens, Chemokine CXCL13, Enzyme-Linked Immunosorbent Assay, Humans, Macrophages, Receptors, CXCR5, Pemphigoid, Bullous, Pemphigus
- Abstract
CXCL13 recruits CXCR5
+ follicular helper T (Tfh) cells in inflammatory lesions to develop secondary lymphoid organs. Tfh cells activate B cells to produce antibodies during humoral immune responses. Indeed, as previous reports suggested, CXCR5+ cell numbers were increased in the peripheral blood of bullous pemphigoid (BP) patients when compared with healthy donors, and the ratio of CXCR5+ cells was positively correlated with the anti-BP180-NC16A titers. From the above findings, in this report, we hypothesized that a chemokine related to CXCR5+ cells, namely CXCL13, may play a role in the development of BP. We performed immunohistochemical staining of CXCR5, CXCL13, LL37, CXCL10 and CCL20 for 10 cases of BP and 10 cases of pemphigus vulgaris (PV), and quantitatively analyzed the staining by digital microscopy. Moreover, we investigated the CXCL10 and CXCL13 production in BP and PV patients by enzyme-linked immunosorbent assay. The immunomodulatory effects of LL37 on the production of T-helper 17-related chemokines were evaluated using monocyte-derived M2 macrophages. Immunohistochemical staining and digital microscopic analysis showed that the ratios of CXCR5+ , CXCL13+ and LL37+ cells in the dermis were significantly higher in BP patients than in PV patients. Notably, the ratio of CXCL13+ cells was positively correlated with the anti-BP180-NC16A titers. Moreover, the serum levels of CXCL13 were positively correlated with the anti-BP180-NC16A titers. Furthermore, CD163+ M2 macrophages stimulated by LL37 in vitro produced CXCL10 and CCL20. In the lesional skin of BP, CD163+ macrophages CXCL10 and CCL20 were produced. The serum levels of CXCL10 were negatively correlated with the anti-BP180-NC16A titers. The present study results indicate that the mechanism of the development of BP may involve the CXCL13/CXCR5-mediated migration of Tfh cells., (© 2020 Japanese Dermatological Association.)- Published
- 2021
- Full Text
- View/download PDF
37. Case series of BRAF-mutated advanced melanoma treated with encorafenib plus binimetinib combination therapy.
- Author
-
Fujimura T, Yoshino K, Kato H, Fujisawa Y, Nakamura Y, Yamamoto Y, Kunimoto K, Ito T, Matsushita S, Maekawa T, Ohuchi K, Amagai R, Muto Y, Furudate S, Kambayashi Y, Hashimoto A, and Aiba S
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, Benzimidazoles, Carbamates, Humans, Mutation, Protein Kinase Inhibitors therapeutic use, Proto-Oncogene Proteins B-raf genetics, Sulfonamides, Melanoma drug therapy, Melanoma genetics, Skin Neoplasms drug therapy, Skin Neoplasms genetics
- Abstract
The efficacy of encorafenib plus binimetinib (E + B) combination therapy for BRAF-mutated advanced melanoma as second-line therapy and beyond is still unknown. In this report, we investigated 22 cases of BRAF-mutated advanced melanoma treated with E + B combination therapy. The objective response rate (ORR) for the total cohort was 68.4%. Notably, the ORR for the second-line and beyond cohort was 73.3%, suggesting that the therapeutic effect of E + B combination therapy is comparable with that of first-line targeted therapy. In contrast, overall survival and progress-free survival in our present cohort was worse than that in a previous clinical trial. Notably, although the incidence rate of severe adverse events was higher than that in a previous report, our present study suggested that E + B combination therapy is a well-tolerated antimelanoma regimen. Our present study suggested that the efficacy and safety profile of E + B combination therapy as a second-line therapy and beyond is comparable with that of first-line targeted therapy., (© 2020 Japanese Dermatological Association.)
- Published
- 2021
- Full Text
- View/download PDF
38. Dabrafenib plus trametinib combination therapy triggered onset of pustulosis palmaris et plantaris in a patient with advanced cutaneous melanoma.
- Author
-
Muto Y, Fujimura T, Kambayashi Y, Ohuchi K, Amagai R, Okuma T, Furudate S, Hashimoto A, and Aiba S
- Subjects
- Antineoplastic Combined Chemotherapy Protocols adverse effects, Humans, Imidazoles, Oximes, Proto-Oncogene Proteins B-raf, Pyridones adverse effects, Pyrimidinones, Melanoma drug therapy, Psoriasis, Skin Neoplasms drug therapy
- Published
- 2021
- Full Text
- View/download PDF
39. Topical and Systemic Formulation Options for Cutaneous T Cell Lymphomas.
- Author
-
Fujimura T, Amagai R, Kambayashi Y, and Aiba S
- Abstract
Although various anti-cutaneous T-cell lymphoma (CTCL) therapies are available for clinical use, appropriate chemotherapy lines for the treatment of CTCLs have yet to be established. Therefore, to date, various clinical trials for the treatment of advanced CTCLs are ongoing. In this review, we evaluate the therapeutic options that are available in clinical practice for treatment of early- and advanced-stage CTCLs (targeted therapies, histone deacetylase (HDAC) inhibitors, retinoids, interferons, cytotoxic drugs, etc.). We also examine clinical trials of novel regimens for the treatment of CTCLs.
- Published
- 2021
- Full Text
- View/download PDF
40. The modified IL-8 Luc assay, an in vitro skin sensitisation test, can significantly improve the false-negative judgment of lipophilic sensitizers with logK ow values > 3.5.
- Author
-
Kimura Y, Fujimura C, and Aiba S
- Subjects
- Cell Line, False Negative Reactions, Gene Expression Regulation, Genes, Reporter, Glyceraldehyde-3-Phosphate Dehydrogenases genetics, Humans, Peptide Fragments genetics, Promoter Regions, Genetic, THP-1 Cells, Allergens toxicity, Animal Testing Alternatives methods, Biological Assay methods, Dermatitis, Allergic Contact, Interleukin-8 genetics, Luciferases genetics, Skin Tests methods
- Abstract
False-negative judgment due to poor chemical solubility is a problem with in vitro skin sensitisation tests. Water-insoluble chemicals are typically dissolved in DMSO in most sensitisation tests but precipitate when diluted with medium beyond their solubility in water. Such tests lack procedures to rule out false-negative judgments due to poor solubility. The IL-8 Luc assay (OECD442E) is unique in that if chemicals do not dissolve at 20 mg/mL in medium and have no effect on IL-8 luciferase activity (IL8LA), they are classified as indeterminate. The purpose of the present study was to reduce the number of indeterminate chemicals and improve assay performance. The IL-8 Luc assay can simultaneously examine glyceraldehyde 3-phosphate dehydrogenase luciferase activity (GAPLA) and IL8LA, and thus we examined the correlation between the reduction of GAPLA (defined as Inh-GAPLA) and the reduction of propidium iodide (PI)-excluding cells for three sensitizers and three non-sensitizers. We observed a significant correlation between luciferase activity driven by the GAPDH promoter of THP-G8 cells and the number of viable cells. Furthermore, chemicals providing an Inh-GAPLA value below 0.8 always reduced the ratio of PI-excluding cells to less than 0.6. Using the modified criteria, indeterminate chemicals are judged as negative if they provide Inh-GAPLA values below 0.8. This modification reduced the number of indeterminate chemicals and increased specificity, highlighting the unique advantage of the IL-8 Luc assay.
- Published
- 2021
- Full Text
- View/download PDF
41. Facial UV photo imaging for skin pigmentation assessment using conditional generative adversarial networks.
- Author
-
Kojima K, Shido K, Tamiya G, Yamasaki K, Kinoshita K, and Aiba S
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Cheek diagnostic imaging, Child, Colorimetry methods, Female, Humans, Male, Middle Aged, Skin Neoplasms prevention & control, Ultraviolet Rays, Young Adult, Face diagnostic imaging, Image Interpretation, Computer-Assisted methods, Pigmentation Disorders diagnosis, Skin Pigmentation physiology
- Abstract
Skin pigmentation is associated with skin damages and skin cancers, and ultraviolet (UV) photography is used as a minimally invasive mean for the assessment of pigmentation. Since UV photography equipment is not usually available in general practice, technologies emphasizing pigmentation in color photo images are desired for daily care. We propose a new method using conditional generative adversarial networks, named UV-photo Net, to generate synthetic UV images from color photo images. Evaluations using color and UV photo image pairs taken by a UV photography system demonstrated that pigment spots were well reproduced in synthetic UV images by UV-photo Net, and some of the reproduced pigment spots were difficult to be recognized in color photo images. In the pigment spot detection analysis, the rate of pigment spot areas in cheek regions for synthetic UV images was highly correlated with the rate for UV photo images (Pearson's correlation coefficient 0.92). We also demonstrated that UV-photo Net was effective for floating up pigment spots for photo images taken by a smartphone camera. UV-photo Net enables an easy assessment of pigmentation from color photo images and will promote self-care of skin damages and early signs of skin cancers for preventive medicine.
- Published
- 2021
- Full Text
- View/download PDF
42. Serum soluble CD163 and proinflammatory chemokines may be biomarkers of the onset of adverse events in dabrafenib plus trametinib combination therapy for advanced melanoma.
- Author
-
Amagai R, Fujimura T, Muto Y, Kambayashi Y, Furudate S, Ohuchi K, Okuma T, Hashimoto A, and Aiba S
- Subjects
- Antineoplastic Combined Chemotherapy Protocols adverse effects, Biomarkers, Chemokines therapeutic use, Humans, Imidazoles, Mutation, Oximes, Proto-Oncogene Proteins B-raf genetics, Pyridones, Pyrimidinones, Melanoma drug therapy, Skin Neoplasms drug therapy
- Abstract
Various adverse events (AEs) have been reported to occur at a high rate in patients treated with dabrafenib plus trametinib (D + T) combination therapy. Among such AEs, the incidence of pyrexia was highest among the series of AEs in patients treated with D + T combination therapy. Although little is known about the mechanisms of pyrexia caused by D + T combination therapy, a recent report suggested that sCD163, as well as interferon-inducible chemokines (CXCL9, CXCL10, CXCL11), might correlate with pyrexia caused by encorafenib plus binimetinib combination therapy. In addition to these soluble factors, CXCL5 is a biomarker for predicting immune-related AEs in melanoma patients treated with nivolumab. From the above findings, we hypothesized that these soluble factors might also correlate with the onset of AEs in D + T combination therapy. The serum levels of sCD163 were increased in patients with pyrexia in parallel with their severity, whereas the serum levels of CXCL5 were increased in patients without pyrexia. Moreover, increased levels of CXCL9, CXCL10, and CXCL11 were prominent in patients with AEs over G2 levels. As these chemokines recruit Th1, Th17, and activated CD8+ T cells, increased serum levels of these chemokines might correlate with the positive feedback of inflammatory reactions related to AEs., (© 2020 Wiley Periodicals LLC.)
- Published
- 2021
- Full Text
- View/download PDF
43. Multiple halo nevi associated with Turner syndrome.
- Author
-
Yamazaki E, Irimada M, Sasaki R, Tsuchiyama K, Yamasaki K, and Aiba S
- Subjects
- Humans, Nevus, Halo, Nevus, Pigmented, Skin Neoplasms complications, Skin Neoplasms diagnosis, Turner Syndrome complications, Turner Syndrome diagnosis
- Published
- 2021
- Full Text
- View/download PDF
44. Severe eczematoid and lichenoid eruption with full-thickness epidermal necrosis developing from metastatic urothelial cancer treated with enfortumab vedotin.
- Author
-
Sasaki R, Fujimura T, Lyu C, and Aiba S
- Subjects
- Antibodies, Monoclonal adverse effects, Humans, Male, Middle Aged, Necrosis, Carcinoma, Transitional Cell, Lichenoid Eruptions chemically induced
- Abstract
Enfortumab vedotin (EV) is a novel, fully humanized monoclonal antibody-drug conjugate composed of an anti-Nectin-4 antibody joined to monomethyl auristatin E. In this report, we described a case of a severe eczematoid and lichenoid eruption with full-thickness epidermal necrosis developing in patients with metastatic urothelial cancer treated with EV. Because phase II and phase III clinical studies are ongoing, in the future, substantial amounts of EV are expected to be used for the treatment of metastatic urothelial cancer. Therefore, understanding the mechanisms of drug eruption caused by EV is important for oncologists as well as dermatologists., (© 2020 Japanese Dermatological Association.)
- Published
- 2020
- Full Text
- View/download PDF
45. Increased serum CCL26 level is a potential biomarker for the effectiveness of anti-PD1 antibodies in patients with advanced melanoma.
- Author
-
Fujimura T, Tanita K, Ohuchi K, Sato Y, Lyu C, Kambayashi Y, Fujisawa Y, Tanaka R, Hashimoto A, and Aiba S
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Humans, Male, Melanoma pathology, Middle Aged, Skin Neoplasms pathology, Biomarkers, Tumor metabolism, Chemokine CCL26 metabolism, Melanoma diagnosis, Skin Neoplasms diagnosis
- Abstract
Nivolumab plus ipilimumab combined therapy is among the most effective therapies for advanced melanoma. However, this therapy is also associated with a high frequency of immune-related adverse events (irAEs). To avoid such severe irAEs caused by additional administration of anti-CTLA4 antibodies, biomarkers to distinguish responders from non-responders among patients treated with anti-PD1 antibodies are important. The purpose of this study is to evaluate the increased serum levels of CCL11, CCL24, and CCL26 as a predictive biomarker for the efficacy of anti-PD1 antibodies in advanced cutaneous melanoma patients. This study analyzed increased serum levels of CCL11, CCL24, and CCL26 in 46 cases of advanced cutaneous melanoma treated with anti-PD1 antibodies. Serum levels on day 42 were compared to baseline (day 0) and analyzed statistically. Receiver operating characteristic curves were established to evaluate the correlation between serum levels of CCL11, CCL24, and CCL26 and efficacy of anti-PD1 antibodies. Increased serum levels of CCL26 correlated significantly with the efficacy of anti-PD1 antibodies. In contrast, no significant correlations were seen between increased serum levels of CCL11 and CCL24 and efficacy of anti-PD1 antibodies. Increased serum levels of CCL26 may be a useful biomarker for identifying those patients with advanced cutaneous melanoma most likely to benefit from anti-melanoma immunotherapy.
- Published
- 2020
- Full Text
- View/download PDF
46. Serum CCL22 levels decreased in parallel with disease activity in CCR4-positive mycosis fungoides treated with mogamulizumab.
- Author
-
Ohuchi K, Fujimura T, Lyu C, Amagai R, Muto Y, and Aiba S
- Subjects
- Antibodies, Monoclonal, Humanized, Chemokine CCL17, Chemokine CCL22, Humans, Receptors, CCR4, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides drug therapy, Skin Neoplasms drug therapy
- Abstract
Mogamulizumab is a humanized anti-C-C chemokine receptor type (CCR)4 antibody that shows cytotoxicity against CCR4+ lymphoma cells via antibody-dependent cell-mediated cytotoxicity in advanced cutaneous T cell lymphoma (CTCL) patients. The production levels of ligands for CCR4, that is, Chemokine (C-C motif) ligand (CCL)17 and CCL22, are important for the assessment of the disease activity in CTCL patients. We evaluated the serum levels of CCL17, CCL19, CCL22, C-X-C motif chemokine ligand (CXCL)10, and CXCL13, which are ligands for CCR4, CCR7, CCR4, C-X-C Motif Chemokine Receptor (CXCR)3, and CXCR5, respectively, at baseline and 4 weeks after the administration of mogamulizumab in five patients with mycosis fungoides. The serum levels of CCL22 were significantly decreased in patients who responded to mogamulizumab, but no differences were identified in the serum levels of CCL17, CCL19, CXCL10, or CXCL13. Immunofluorescence staining revealed that the majority of CCL22-producing cells were cluster of differentiation (CD)163+ tumor-associated macrophages, and they were surrounded by CCR4+ CTCL cells. Our present data suggested that the serum CCL22 level may be a predictive marker of the efficacy of mogamulizumab for the treatment of CCR4+ CTCL., (© 2020 Wiley Periodicals LLC.)
- Published
- 2020
- Full Text
- View/download PDF
47. Multiple angiolymphoid hyperplasia with eosinophilia on the right arm showing unusual presentation.
- Author
-
Tamabuchi E, Fujimura T, Lyu C, and Aiba S
- Subjects
- Arm, Humans, Angiolymphoid Hyperplasia with Eosinophilia diagnosis, Leukocyte Disorders
- Published
- 2020
- Full Text
- View/download PDF
48. Erythema nodosum developed in a patient with advanced cutaneous melanoma treated with dabrafenib plus trametinib combination therapy.
- Author
-
Muto Y, Fujimura T, Kambayashi Y, Ohuchi K, Amagai R, Okuma T, Furudate S, Hashimoto A, and Aiba S
- Subjects
- Antineoplastic Combined Chemotherapy Protocols adverse effects, Humans, Imidazoles, Mutation, Oximes, Proto-Oncogene Proteins B-raf genetics, Pyridones, Pyrimidinones, Erythema Nodosum, Melanoma drug therapy, Skin Neoplasms drug therapy
- Published
- 2020
- Full Text
- View/download PDF
49. Possible Roles of Proinflammatory Signaling in Keratinocytes Through Aryl Hydrocarbon Receptor Ligands for the Development of Squamous Cell Carcinoma.
- Author
-
Sato Y, Fujimura T, Hidaka T, Lyu C, Tanita K, Matsushita S, Yamamoto M, and Aiba S
- Subjects
- Animals, Anthracenes toxicity, Carbazoles toxicity, Carcinoma, Squamous Cell chemically induced, Carcinoma, Squamous Cell genetics, Carcinoma, Squamous Cell pathology, Cytokines genetics, Cytokines immunology, Humans, Inflammation chemically induced, Inflammation genetics, Inflammation immunology, Inflammation pathology, Keratinocytes pathology, Mice, Mice, Inbred BALB C, Mice, Transgenic, Neoplasm Proteins genetics, Piperidines toxicity, Receptors, Aryl Hydrocarbon genetics, Signal Transduction drug effects, Skin Neoplasms chemically induced, Skin Neoplasms genetics, Skin Neoplasms pathology, Carcinoma, Squamous Cell immunology, Keratinocytes immunology, Neoplasm Proteins immunology, Receptors, Aryl Hydrocarbon immunology, Signal Transduction immunology, Skin Neoplasms immunology
- Abstract
Aryl hydrocarbon receptor (AhR) provides a deeper insight into the pathogenesis of cutaneous squamous cell carcinoma (cSCC). AhR ligands, such as 6-formylindolo[3,2-b] carbazole (FICZ), and 7,12-Dimethylbenz[a]anthracene (DMBA), constitute major substrates for the cytochrome P450 (CYP) family, and influence the expression of various cytokine genes, including IL-17 and IL-23 -related genes via the AhR. On the other hand, proinflammatory cytokines could drive tumor progression through the TRAF-ERK5 signaling pathway in cSCC. From the above findings, we hypothesized that AhR ligands might enhance the mRNA expression of proinflammatory cytokines via the AhR, leading to the development of cSCC. The purpose of this study was to investigate (1) the immunomodulatory effects of FICZ and DMBA on normal human keratinocytes (NHKCs), focusing on IL-17, and related cytokines/chemokines (IL-23, IL-36γ, and CCL20), (2) the expression of these factors in AhR-dependent pathways using a two-stage chemically induced skin carcinogenesis mouse model, and (3) the expression of these factors in lesion-affected skin in cSCC. Both FICZ and DMBA augmented the expression of CYP1A1, p19, CCL20, and IL-36γ mRNA in NHKCs in vitro . Moreover, the mRNA expression of these proinflammatory factors, as well as IL-17, in mouse cSCC is significantly decreased in the AhR-(fl/fl) Krt5-(Cre) mice compared to wild type mice, leading to a decrease in the number of developed cSCC lesions. Furthermore, CCL20, IL-23, as well as IL-17, are detected in the lesion-affected skin of cSCC patients. Our study demonstrates a possible mechanism for the development of cSCC involving AhR-mediated signaling by epidermal keratinocytes and recruitment of Th17 cells., (Copyright © 2020 Sato, Fujimura, Hidaka, Lyu, Tanita, Matsushita, Yamamoto and Aiba.)
- Published
- 2020
- Full Text
- View/download PDF
50. Short anagen syndrome: A unique short hair syndrome without any characteristic hair morphological abnormality.
- Author
-
Segawa Y, Yamasaki K, Otake E, Kikuchi K, and Aiba S
- Subjects
- Alopecia diagnosis, Alopecia genetics, Hair, Hair Follicle, Humans, Syndrome, Hair Diseases diagnosis, Hair Diseases genetics
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.